Results 91 to 100 of about 24,911 (203)

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights [PDF]

, 2010
Prognostic markers, such as NPM1, Flt3-ITD, and cytogenetic abnormalities have made it possible to formulate aggressive treatment plans for unfavorable acute myeloid leukemia (AML).
Xiongpeng Zhu, Yuehua Ma, Delong Liu
core   +2 more sources

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source

Epigenetics in diagnosis, prognostic assessment and treatment of cancer:An update [PDF]

, 2014
Cancer cells contain multiple genetic and epigenetic changes. The relative specificity of many epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic and predictive biomarkers for a number of solid tumors and ...
Briasoulis, Evangelos, Crook, Tim, Hatzimichael, Eleftheria, Lagos, Konstantinos, Sim, Van Ren   +4 more
core   +4 more sources

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Immunoprofiling, sex‐ and age‐related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma

British Journal of Haematology, Volume 208, Issue 5, Page 1617-1630, May 2026.
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re, Egesta Lopci, Giulia Brisotto, Caterina Elia, Angelo Vitullo, Veronica Paduano, Mariangela De Zorzi, Lara Mussolin, Paola Quarello, Simona Bianchi, Salvatore Buffardi, Alberto Garaventa, Paola Muggeo, Marta Pillon, Alessandra Sala, Luciana Vinti, Emanuele d'Amore, Christine Mauz‐Korholz, Maurizio Mascarin, on behalf of the AIEOP Hodgkin's Lymphoma Study Group, Alberto Garaventa, Alessandra Sala, Antonella Sau, Assunta Tornesello, Daniela Galimberti, Domenico Sperlì, Elena Facchini, Eulalia Galea, Federico Verzegnassi, Fiorina Giona, Francesca Rossi, Fulvio Porta, Irene D’Alba, Katia Perruccio, Luciana Vinti, Marco Zecca, Marta Pillon, Massimo Provenzi, Maurizio Bianchi, Maurizio Mascarin, Monica Cellini, Nadia Vacca, Paola Muggeo, Patrizia Bertolini, Piero Farruggia, Raffaella De Santis, Roberta Pericoli, Rosamaria Mura, Salvatore Buffardi, Salvatore D’Amico, Sayla Bernasconi, Simona Rinieri, Simone Cesaro, Tommaso Casini, Valerio Cecinati   +54 more
wiley   +1 more source

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

Haematologica, 2012
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting.
Michael Lübbert, Björn H. Rüter, Rainer Claus, Claudia Schmoor, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Konstanze Döhner, Anne Hagemeijer, Pierre W. Wijermans, Hartmut Döhner   +18 more
doaj   +1 more source

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. [PDF]

, 2019
Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality, especially for older patients and those with relapsed/refractory (R/R) disease.
Galkin, Maria, Jonas, Brian A
core   +1 more source

Fucoidan: An Update on Function, Role in Human Health and Applications

Chemical Biology &Drug Design, Volume 107, Issue 5, May 2026.
Fucoidan is a promising bioactive compound with anti‐inflammatory, anticoagulant, anticancer, antioxidant, antiviral, and cardioprotective properties. In addition, thanks to its epigenetic potential, ability to modulate autophagic mechanisms and possibility adjuvant agent or bioactive component of the drug delivery systems, fucoidan is a promising ...
Sharon Critelli, Marilena Celano
wiley   +1 more source

Physicochemical Stability of Reconstituted Decitabine (Dacogen®) Solutions and Ready-to-Administer Infusion Bags when Stored Refrigerated or Frozen

Pharmaceutical Technology in Hospital Pharmacy, 2017
Profound knowledge about the physicochemical stability is necessary in order to determine the “beyond-use-dates” of ready-to-administer preparations after reconstitution and dilution.
Kim Sun Hee, Heeb Rita Marina, Krämer Irene   +2 more
doaj   +1 more source